Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Immuneering Corporation has received a consensus rating of "Moderate Buy" from five analysts, with one sell and four buy ratings, and an average target price of $13.25.
• Insiders, including Director Peter Feinberg and CEO Benjamin J. Zeskind, have recently increased their holdings, with Feinberg purchasing 25,000 shares and Zeskind acquiring 21,000 shares.
• The stock opened at $3.25, with a one-year low of $1.00 and a high of $4.69, while currently 67.65% of shares are held by institutional investors.

Shares of Immuneering Corporation (NASDAQ:IMRX - Get Free Report) have been given an average rating of "Moderate Buy" by the five brokerages that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $13.25.

A number of analysts have issued reports on IMRX shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $9.00 price objective on shares of Immuneering in a research note on Wednesday, June 18th. Oppenheimer reduced their price objective on Immuneering from $25.00 to $21.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Mizuho lifted their price objective on Immuneering from $8.00 to $10.00 and gave the stock an "outperform" rating in a research note on Wednesday, June 18th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $13.00 price objective on shares of Immuneering in a research note on Wednesday, June 18th.

Insider Transactions at Immuneering

In related news, Director Peter Feinberg bought 25,000 shares of the company's stock in a transaction dated Wednesday, June 18th. The stock was purchased at an average price of $2.53 per share, for a total transaction of $63,250.00. Following the acquisition, the director owned 136,766 shares in the company, valued at $346,017.98. This trade represents a 22.37% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Benjamin J. Zeskind bought 21,000 shares of the company's stock in a transaction dated Wednesday, June 18th. The stock was bought at an average price of $2.39 per share, with a total value of $50,190.00. Following the acquisition, the chief executive officer owned 2,302,852 shares in the company, valued at approximately $5,503,816.28. This trade represents a 0.92% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 127,507 shares of company stock worth $334,318. 22.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Immuneering

Institutional investors and hedge funds have recently modified their holdings of the stock. Tang Capital Management LLC purchased a new position in Immuneering during the 4th quarter valued at $27,000. Jane Street Group LLC purchased a new position in Immuneering during the 1st quarter valued at $32,000. Kingsview Wealth Management LLC purchased a new position in Immuneering during the 2nd quarter valued at $47,000. Marshall Wace LLP purchased a new position in Immuneering during the 4th quarter valued at $47,000. Finally, First Manhattan CO. LLC. purchased a new position in Immuneering during the 4th quarter valued at $71,000. Hedge funds and other institutional investors own 67.65% of the company's stock.

Immuneering Trading Down 8.1%

IMRX traded down $0.26 on Friday, hitting $2.96. 363,852 shares of the company's stock traded hands, compared to its average volume of 1,238,543. The company's 50 day simple moving average is $3.33 and its 200-day simple moving average is $2.17. The firm has a market cap of $106.52 million, a price-to-earnings ratio of -1.51 and a beta of 0.37. Immuneering has a one year low of $1.00 and a one year high of $4.69.

Immuneering (NASDAQ:IMRX - Get Free Report) last issued its earnings results on Tuesday, August 19th. The company reported ($0.40) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.40). As a group, equities analysts anticipate that Immuneering will post -1.86 EPS for the current fiscal year.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.